志道生物是一家國(guó)際領(lǐng)先的抗腫瘤細(xì)胞因子藥物研發(fā)企業(yè)，具有國(guó)內(nèi)最全面的抗腫瘤細(xì)胞因子開發(fā)管線和最多的相關(guān)專利數(shù)量。其核心管線LTC004在中美臨床I期階段，為國(guó)內(nèi)進(jìn)度最快，給藥劑量全球領(lǐng)先的可成藥細(xì)胞因子管線。其高效的分子設(shè)計(jì)平臺(tái)與核心專利蛋白質(zhì)定向變復(fù)性技術(shù)突破現(xiàn)有專利壁壘并有效降低研發(fā)成本。志道生物于2014年在北京成立，核心團(tuán)隊(duì)成員多來自諾和諾德、強(qiáng)生等頭部藥企，平均15+年產(chǎn)業(yè)及研發(fā)經(jīng)驗(yàn)。志道生物目前以完成多輪融資，目前已與多家頭部藥企合作，實(shí)現(xiàn)項(xiàng)目轉(zhuǎn)讓/對(duì)外授權(quán)超10項(xiàng)。
Leto Laboratories is a world leading biotech in anti-tumor cytokine drug development with the broadest anti-tumor cytokine pipelines and the largest number of related patents in China. The leading asset LTC004 is in the Phase I clinical study in China and the United States, the fastest advanced druggable cytokine in China with global-leading dosage administration. The proprietary protein renaturation technology break through existing patent barriers and provide significant cost leadership. Leto Labs was established in Beijing in 2014. Core team all comes from the leading pharmaceutical companies, Novo Nordisk and Johnson & Johnson, etc., with an average of 15+ years of industry and R&D experience. At present, Leto Labs completed multiple rounds of financing, and has partnered with a number of leading pharma with tech-transfer/out-licensing of more than 10 projects.